<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title> &#187; adenoviruses</title>
	<atom:link href="http://pharmaexecnews.com/tag/adenoviruses/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmaexecnews.com</link>
	<description></description>
	<lastBuildDate>Wed, 08 Sep 2010 08:00:50 +0000</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
			<item>
		<title>Researchers get $21M to Study HIV</title>
		<link>http://pharmaexecnews.com/biotechnology/researchers-21m-study-hiv/</link>
		<comments>http://pharmaexecnews.com/biotechnology/researchers-21m-study-hiv/#comments</comments>
		<pubDate>Thu, 26 Aug 2010 08:00:51 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10648</guid>
		<description><![CDATA[A team headed by researchers from the Salk Institute for Biological Studies and the Sanford-Burnham Medical Research Institute has been awarded a $21 million grant to ascertain how the immune system reacts immediately after it is exposed to the AIDS virus. The project will bring together the expertise of 13 research groups at seven institutions [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/researchers-21m-study-hiv/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Biotech M&amp;A Frenzy Shows no Sign of Slowing</title>
		<link>http://pharmaexecnews.com/biotechnology/biotech-ma-frenzy-shows-sign-slowing/</link>
		<comments>http://pharmaexecnews.com/biotechnology/biotech-ma-frenzy-shows-sign-slowing/#comments</comments>
		<pubDate>Wed, 18 Aug 2010 08:00:06 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10614</guid>
		<description><![CDATA[With Genzyme in the news, we&#8217;ve all been hearing plenty about the wave of M&#38;A deals that&#8217;s been rolling through the world&#8217;s life sciences industry. Last year, Thomson Reuters tracked more than 1,400 such deals worth $206 billion worldwide, giving the Boston Globe the hard numbers it needs to assert that this is one trend [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/biotech-ma-frenzy-shows-sign-slowing/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Sanofi, Genzyme Far Apart on Buyout Price</title>
		<link>http://pharmaexecnews.com/biotechnology/sanofi-genzyme-buyout-price/</link>
		<comments>http://pharmaexecnews.com/biotechnology/sanofi-genzyme-buyout-price/#comments</comments>
		<pubDate>Wed, 04 Aug 2010 08:00:29 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Genomics]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10569</guid>
		<description><![CDATA[The bidding on Genzyme has begun, with Sanofi putting down a hard offer of $69 a share, according to the Wall Street Journal. But Reuters and others have their own sources who say that Genzyme&#8217;s board wants to hold out for at least $80 a share, and possibly wait to see if another bidder steps [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/sanofi-genzyme-buyout-price/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Merck Buys Vax Unit from Bankrupt Hawaii Biotech</title>
		<link>http://pharmaexecnews.com/biotechnology/merck-buys-vax-unit-bankrupt-hawaii-biotech/</link>
		<comments>http://pharmaexecnews.com/biotechnology/merck-buys-vax-unit-bankrupt-hawaii-biotech/#comments</comments>
		<pubDate>Tue, 03 Aug 2010 08:00:24 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding Genomics and Global Health Impacts]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10559</guid>
		<description><![CDATA[Merck (NYSE: MRK) has agreed to purchase bankrupt Hawaii Biotech&#8217;s dengue fever vaccine unit for an undisclosed sum. It&#8217;s a critical move for Hawaii, which filed for Chapter 11 bankruptcy protection last year and will deplete a $2 million credit line by the end of this month. The sale leaves Hawaii with a West Nile virus vaccine [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/merck-buys-vax-unit-bankrupt-hawaii-biotech/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Milestones Mitigate Risk in Biotech Deals</title>
		<link>http://pharmaexecnews.com/biotechnology/milestones-mitigate-risk-biotech-deals/</link>
		<comments>http://pharmaexecnews.com/biotechnology/milestones-mitigate-risk-biotech-deals/#comments</comments>
		<pubDate>Thu, 29 Jul 2010 08:00:23 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Genomics]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[Nanotechnology]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Proteomics]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Strategy]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[Breast cancer]]></category>
		<category><![CDATA[c reactive protein]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[Gene therapy]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding Genomics and Global Health Impacts]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10551</guid>
		<description><![CDATA[Milestone payments are becoming an increasingly familiar aspect of many biotech deals, as buyers try to mitigate the risks inherent with big purchases. Take Celgene&#8217;s $2.9 billion buyout of Abraxis; the biotech giant set aside $650 million in milestone payments if Abraxis&#8217; key drug Abraxane hit certain goals. &#8220;These structures are a great way for [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/milestones-mitigate-risk-biotech-deals/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Fastest Growing Therapeutic Classes (by Sales)</title>
		<link>http://pharmaexecnews.com/biotechnology/fastest-growing-therapeutic-classes-sales/</link>
		<comments>http://pharmaexecnews.com/biotechnology/fastest-growing-therapeutic-classes-sales/#comments</comments>
		<pubDate>Tue, 27 Jul 2010 08:00:34 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Analgesics]]></category>
		<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Cardiovascular]]></category>
		<category><![CDATA[Central Nervous System]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Respiratory]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[Breast cancer]]></category>
		<category><![CDATA[c reactive protein]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[lymph]]></category>
		<category><![CDATA[lymphoma]]></category>
		<category><![CDATA[micro technology]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Pharmacogenomics]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Proteomics]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10540</guid>
		<description><![CDATA[Oncologics, lipid regulators, respiratory agents, antidiabetics and anti-ulcerants are the five largest drug classes by sales. But annual sales are only half the story. Which drug classes are booming, and which have plateaued&#8211;or even dropped? IMS Health has released top-line industry data revealing the 15 largest drug classes, and we&#8217;ve crunched the numbers to take a closer [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/fastest-growing-therapeutic-classes-sales/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pipeline to Soften Lilly Patent Losses</title>
		<link>http://pharmaexecnews.com/biotechnology/pipeline-soften-lilly-patent-losses/</link>
		<comments>http://pharmaexecnews.com/biotechnology/pipeline-soften-lilly-patent-losses/#comments</comments>
		<pubDate>Mon, 26 Jul 2010 08:00:06 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Central Nervous System]]></category>
		<category><![CDATA[Clinical Trials]]></category>
		<category><![CDATA[Companies]]></category>
		<category><![CDATA[Deals and Mergers]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Drug Trials]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Generics]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[International News]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Patents]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[New Drugs]]></category>
		<category><![CDATA[Oncology]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Strategy]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[Breast cancer]]></category>
		<category><![CDATA[c reactive protein]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[generic drugs]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[nanobiotechnology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical companies]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Prostate Cancer]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10536</guid>
		<description><![CDATA[Eli Lilly (NYSE: LLY) is looking to its pipeline to fill the gaps left by a number of high-profile drugs coming off patent. In October 2011, blockbuster Zyprexa will fall to generic competition; additionally, about three-quarters of Lilly&#8217;s current revenue comes from eight drugs that will lose patent protection between now and 2017. &#8221;We have the challenge [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/pipeline-soften-lilly-patent-losses/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Scientists Grow New Lungs Using &#8216;Skeletons&#8217; of Old Ones</title>
		<link>http://pharmaexecnews.com/biotechnology/scientists-grow-lungs-skeletons/</link>
		<comments>http://pharmaexecnews.com/biotechnology/scientists-grow-lungs-skeletons/#comments</comments>
		<pubDate>Fri, 09 Jul 2010 08:00:57 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Genomics]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[Proteomics]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[biochip]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[c reactive protein]]></category>
		<category><![CDATA[cancer therapies]]></category>
		<category><![CDATA[embryonic stem cell research]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Gene therapy]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[micro technology]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Pharmacogenomics]]></category>
		<category><![CDATA[polymerase chain reaction]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[understanding stem cell research]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10471</guid>
		<description><![CDATA[For someone with a severe, incurable lung disorder such as cystic fibrosis or chronic obstructive pulmonary disease, a lung transplant may be the only chance for survival. Unfortunately, it&#8217;s often not a very good chance. Matching donor lungs are rare, and many would-be recipients die waiting for the transplants that could save their lives.

Such deaths [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/scientists-grow-lungs-skeletons/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Antiviral Stem Cell Squad Dispatched to Fight Deadly HIV</title>
		<link>http://pharmaexecnews.com/biotechnology/antiviral-stem-cell-squad-dispatched-fight-deadly-hiv/</link>
		<comments>http://pharmaexecnews.com/biotechnology/antiviral-stem-cell-squad-dispatched-fight-deadly-hiv/#comments</comments>
		<pubDate>Thu, 08 Jul 2010 08:00:25 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Genomics]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Immune Disorders]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Industry News Alerts]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Proteomics]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech news]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[dna]]></category>
		<category><![CDATA[dna sequence]]></category>
		<category><![CDATA[embryonic stem cell research]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[Gene therapy]]></category>
		<category><![CDATA[genetics]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[Nanotechnology - Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Pharmacogenomics]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding Genomics and Global Health Impacts]]></category>
		<category><![CDATA[understanding stem cell research]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10467</guid>
		<description><![CDATA[Building on research work undertaken in Germany, City of Hope investigators near LA have used modified stem cells loaded with gene sequences to fight off HIV. And the scientists in the study say that the work points to a possible cure for the dread virus, which has killed millions of people around the world.

Researchers opted [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/antiviral-stem-cell-squad-dispatched-fight-deadly-hiv/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Bio-terror Lab Will Target Infectious Disease Therapies</title>
		<link>http://pharmaexecnews.com/biotechnology/bioterror-lab-target-infectious-disease-therapies/</link>
		<comments>http://pharmaexecnews.com/biotechnology/bioterror-lab-target-infectious-disease-therapies/#comments</comments>
		<pubDate>Tue, 06 Jul 2010 08:00:36 +0000</pubDate>
		<dc:creator>admin</dc:creator>
				<category><![CDATA[Bioinformatics]]></category>
		<category><![CDATA[Biomedical]]></category>
		<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Disease]]></category>
		<category><![CDATA[Drug Delivery]]></category>
		<category><![CDATA[Drug Discovery]]></category>
		<category><![CDATA[Financial]]></category>
		<category><![CDATA[General News]]></category>
		<category><![CDATA[Government Policy]]></category>
		<category><![CDATA[Industry News]]></category>
		<category><![CDATA[Infectious Diseases]]></category>
		<category><![CDATA[Market News]]></category>
		<category><![CDATA[Markets]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[Medical Research]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Research Reports]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Vaccines]]></category>
		<category><![CDATA[Virus]]></category>
		<category><![CDATA[adenoviruses]]></category>
		<category><![CDATA[biochip]]></category>
		<category><![CDATA[biochips]]></category>
		<category><![CDATA[bioengineering]]></category>
		<category><![CDATA[Bioinformatics Market Potential]]></category>
		<category><![CDATA[biomolecules]]></category>
		<category><![CDATA[biotech]]></category>
		<category><![CDATA[biotech industry]]></category>
		<category><![CDATA[biotechnology industry]]></category>
		<category><![CDATA[biotechnology news]]></category>
		<category><![CDATA[molecular biology]]></category>
		<category><![CDATA[pharmaceutical industry]]></category>
		<category><![CDATA[Strategic Alliances in World Pharma and Biotech Markets]]></category>
		<category><![CDATA[Understanding the Global Biotech Industry]]></category>
		<category><![CDATA[Understanding the Global Pharmaceutical Market]]></category>

		<guid isPermaLink="false">http://pharmaexecnews.com/?p=10459</guid>
		<description><![CDATA[A new, $50 million biomedical research lab has been completed at George Mason University near Washington D.C. and is being ramped up to study new therapies for infectious diseases&#8211;including a range of potential bioterror weapons.  Once the 52,000-square-foot facility is licensed and fully operational in a few months, 50 people will be on site to [...]]]></description>
		<wfw:commentRss>http://pharmaexecnews.com/biotechnology/bioterror-lab-target-infectious-disease-therapies/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
